The relationship between the menstrual cycle and female sexual interest in women with PMS complaints and volunteers.

This study assesses the influence of menstrual cycle phases and hormones on female sexual interest in both a nonclinical sample of volunteers (n = 18) and women who complained of premenstrual tension (n = 150). Women were assessed prospectively for two menstrual cycles with daily symptom charts. In addition mental status was assessed clinically and the Moos Menstrual Distress Questionnaire completed in the follicular and premenstrual phases. On the basis of these assessments women were assigned to subject groups. During the second cycle, daily 24-h urinary estrogens and urinary pregnanediol were determined. Sexual interest and feelings of well-being were recorded on a daily symptom rating chart. Sexual interest was found to be significantly higher in the follicular and ovulatory phases, than in the luteal, premenstrual, or menstrual phases. Sexual interest and feelings of well-being were correlated (R = 0.29). Sexual interest and feelings of well-being were not correlated with urinary estrogen or pregnanediol levels.

Serial reaction time as a function of the nature of repeated events.

Past research into the phenomenon of reduced latency to repeated events in serial reaction time tasks resulted in attempts to partition reaction time into components attributable to separate cognitive processes. These attempts focused on many-to-one condensing paradigms, which permitted direct assessment of the effect of response-only repetitions but not stimulus-only repetitions. The three experiments reported in the present study used a technique designed to overcome this limitation. It was found that repetition of only the symbolic content of the total stimulus-response event was a sufficient condition for a reduced response latency and that response-only repetitions tended to be facilitative only when stimulus-response relations were compatible. These and related findings were discussed with respect to their bearing on contemporary issues concerning the analysis of cognitive operations into separable and additive components.

Treatment of premenstrual syndrome. A double-blind trial of dydrogesterone.

A double-blind randomised crossover trial of oral micronised progesterone and placebo had demonstrated that progesterone had beneficial effects over placebo for some mood and physical premenstrual symptoms. A further trial using identical methodology was carried out to assess whether dydrogesterone would have the same beneficial effects. Prospective assessment confirmed the presence of a premenstrual syndrome in 30 women. Of these, six withdrew during the 4 months of the study. Twenty-four women completed the double-blind crossover protocol. All women were interviewed premenstrually before treatment and in each month of treatment. They completed the Moos Menstrual Distress Questionnaire, Beck Depression Inventory, Spielberger State Anxiety Inventory, Mood Adjective Checklist and a Daily Symptom Record. Analysis of data found an overall beneficial effect of being treated for most variables. Further analysis showed that the most major effects occurred in the first 2 treatment months. This study could find no evidence that dydrogesterone was more effective than placebo in treating premenstrual complaints.

The nature and assessment of general well-being.

Data on self-reported symptoms of ill-health were collected from 1500 respondents, and factor analysed. The results of this analysis suggested a two factor orthogonal model of well-being: one factor reflecting fatigue, emotional fragility and confusion (worn-out) and the other tension, anxiety and agitation (up-tight). The reliability and validity of the model were tested and appeared acceptable, and scales were constructed for the assessment of the two factors. It is suggested that the model and the associated scales could offer new information in studies of occupational stress and health.

Premenstrual complaints: an idiosyncratic syndrome.

The two issues of premenstrual syndrome (PMS) symptom heterogeneity and symptom severity are addressed in an examination of the idiosyncratic nature of premenstrual complaints. Analyses of PMS symptoms reported during the first assessment month by a group of treatment-seeking women revealed that when presented with a prepared list of symptoms (Menstrual Distress Questionnaire), they select many more symptoms than when self-reporting their complaints in ranked order of severity. In this study of a sample of 98 women, most of the women reported only four rank-ordered symptoms. Symptom profiles from five symptom categories were constructed for each of the women and from a possible 86 different profiles 84 were discovered. Of these, psychological profiles dominated the total reports. These findings, together with results of previous research, lead to two conclusions. First, that PMS, though multidimensional, may be defined for each woman by a limited number of symptoms; and second, that PMS is highly idiosyncratic in nature.

Menstrual cycle hormonal profiles of women with and without premenstrual syndrome.

This paper compares the urinary hormone profiles of estrogen and pregnanediol in women with documented premenstrual syndrome (PMS) (n = 65) and asymptomatic volunteers (n = 18). Daily 24-h urine samples were collected for an entire menstrual cycle. Subject groups did not differ significantly in menses length or in the day of the preovulatory estrogen peak. Cycle length was significantly shorter for the volunteers (p < 0.05). The day of the pregnanediol peak occurred significantly later for the PMS patient group than for the asymptomatic volunteers (p < 0.05). Split plot analysis of variance showed no significant differences overall between subject groups for levels of urinary estrogen or pregnanediol. This study did not find evidence of progesterone deficiency amongst sufferers of the premenstrual syndrome.

Effects of age and non-hormonal contraception on menstrual cycle characteristics.

The objective of this study was to investigate the effects of age and non-hormonal contraceptive method on menstrual cycle parameters. The menstrual cycle data were collected prospectively, and the study was cross-sectional with regard to age. The subjects were 142 women, including 14 asymptomatic volunteers and 128 women who presented to a premenstrual tension (PMT) clinic. The age range was 20-45 years. Contraceptive methods used were intrauterine device (IUD) (n = 12), tubal ligation (n = 61) and non-intensive methods (n = 69). Daily menstrual cycle diaries were used to calculate cycle length and number of days of menstruation. Daily 24-h urine collections were used to calculate the day of the preovulatory estrogen peak. Pearson correlations found significant relationships between age and preovulatory estrogen peak day (p < 0.001) and length of cycle (p < 0.002), but not between age and length of menstruation or luteal phase. Analysis of variance was highly significant for age and contraceptive method, for both cycle length and preovulatory estrogen peak day. Non-intrusive contraception users aged 30 years and younger had significantly longer follicular phases than did women with tubal ligation (p < 0.05). It was concluded that cycle length decreases with age due to shortening of the follicular phase. Further research on whether tubal ligation affects ovulation and follicular phase length in young women is needed.

Progesterone and the premenstrual syndrome: a double blind crossover trial.

A double blind, randomised, crossover trial of oral micronised progesterone (two months) and placebo (two months) was conducted to determine whether progesterone alleviated premenstrual complaints. Twenty three women were interviewed premenstrually before treatment and in each month of treatment. They completed Moos's menstrual distress questionnaire, Beck et al's depression inventory, Spielberger et al's state anxiety inventory, the mood adjective checklist, and a daily symptom record. Analyses of data found an overall beneficial effect of being treated for all variables except restlessness, positive moods, and interest in sex. Maximum improvement occurred in the first month of treatment with progesterone. Nevertheless, an appreciably beneficial effect of progesterone over placebo for mood and some physical symptoms was identifiable after both one and two months of treatment. Further studies are needed to determine the optimum duration of treatment.